Bristol-Myers Squibb Company PFD CONV 2
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis… Read more
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) - Net Assets
Latest net assets as of September 2024: $17.20 Billion USD
Based on the latest financial reports, Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) has net assets worth $17.20 Billion USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($93.67 Billion) and total liabilities ($76.47 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $17.20 Billion |
| % of Total Assets | 18.36% |
| Annual Growth Rate | 5.2% |
| 5-Year Change | -42.97% |
| 10-Year Change | 96.79% |
| Growth Volatility | 240.86 |
Bristol-Myers Squibb Company PFD CONV 2 - Net Assets Trend (1987–2023)
This chart illustrates how Bristol-Myers Squibb Company PFD CONV 2's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bristol-Myers Squibb Company PFD CONV 2 (1987–2023)
The table below shows the annual net assets of Bristol-Myers Squibb Company PFD CONV 2 from 1987 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $29.48 Billion | -5.25% |
| 2022-12-31 | $31.12 Billion | -13.58% |
| 2021-12-31 | $36.01 Billion | -4.95% |
| 2020-12-31 | $37.88 Billion | -26.72% |
| 2019-12-31 | $51.70 Billion | +1461.87% |
| 2018-12-31 | $3.31 Billion | -72.06% |
| 2017-12-31 | $11.85 Billion | -27.53% |
| 2016-12-31 | $16.35 Billion | +13.33% |
| 2015-12-31 | $14.42 Billion | -3.73% |
| 2014-12-31 | $14.98 Billion | -1.66% |
| 2013-12-31 | $15.24 Billion | +11.72% |
| 2012-12-31 | $13.64 Billion | -14.05% |
| 2011-12-31 | $15.87 Billion | +1.46% |
| 2010-12-31 | $15.64 Billion | +5.77% |
| 2009-12-31 | $14.79 Billion | +20.78% |
| 2008-12-31 | $12.24 Billion | +15.90% |
| 2007-12-31 | $10.56 Billion | +5.72% |
| 2006-12-31 | $9.99 Billion | -10.86% |
| 2005-12-31 | $11.21 Billion | +9.86% |
| 2004-12-31 | $10.20 Billion | +4.25% |
| 2003-12-31 | $9.79 Billion | +9.13% |
| 2002-12-31 | $8.97 Billion | -16.48% |
| 2001-12-31 | $10.74 Billion | +16.95% |
| 2000-12-31 | $9.18 Billion | +6.19% |
| 1999-12-31 | $8.64 Billion | +14.11% |
| 1998-12-31 | $7.58 Billion | +4.95% |
| 1997-12-31 | $7.22 Billion | +9.88% |
| 1996-12-31 | $6.57 Billion | +12.85% |
| 1995-12-31 | $5.82 Billion | +2.07% |
| 1994-12-31 | $5.70 Billion | -3.97% |
| 1993-12-31 | $5.94 Billion | -1.33% |
| 1992-12-31 | $6.02 Billion | +3.88% |
| 1991-12-31 | $5.79 Billion | +6.96% |
| 1990-12-31 | $5.42 Billion | +6.57% |
| 1989-12-31 | $5.08 Billion | +2.75% |
| 1988-12-31 | $4.95 Billion | +4.06% |
| 1987-12-31 | $4.75 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bristol-Myers Squibb Company PFD CONV 2's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 526.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $28.77 Billion | 97.74% |
| Common Stock | $292.00 Million | 0.99% |
| Other Comprehensive Income | $-1.55 Billion | -5.25% |
| Other Components | $1.92 Billion | 6.52% |
| Total Equity | $29.43 Billion | 100.00% |
Bristol-Myers Squibb Company PFD CONV 2 Competitors by Market Cap
The table below lists competitors of Bristol-Myers Squibb Company PFD CONV 2 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
A1 Investments & Resources Ltd
AU:AYI
|
$9.45 Million |
|
GTL Limited
NSE:GTL
|
$9.45 Million |
|
PCF Group SA
WAR:PCF
|
$9.45 Million |
|
Wing Yip Food (China) Holdings Group Limited
KQ:900340
|
$9.45 Million |
|
Farminveste, S.G.P.S., S.A.
LS:MLFMV
|
$9.44 Million |
|
Venus Metals Corporation Ltd
AU:VMC
|
$9.44 Million |
|
ALMA METALS LTD. CUFS1
F:BP60
|
$9.44 Million |
|
Q Capital Partners Co. Ltd
KQ:016600
|
$9.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bristol-Myers Squibb Company PFD CONV 2's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 31,061,000,000 to 29,430,000,000, a change of -1,631,000,000 (-5.3%).
- Net income of 8,025,000,000 contributed positively to equity growth.
- Dividend payments of 4,744,000,000 reduced retained earnings.
- Share repurchases of 5,155,000,000 reduced equity.
- Other comprehensive income decreased equity by 265,000,000.
- Other factors increased equity by 508,000,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $8.03 Billion | +27.27% |
| Dividends Paid | $4.74 Billion | -16.12% |
| Share Repurchases | $5.16 Billion | -17.52% |
| Other Comprehensive Income | $-265.00 Million | -0.9% |
| Other Changes | $508.00 Million | +1.73% |
| Total Change | $- | -5.25% |
Book Value vs Market Value Analysis
This analysis compares Bristol-Myers Squibb Company PFD CONV 2's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.60x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 345.99x to 4.60x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1987-12-31 | $2.90 | $1003.20 | x |
| 1988-12-31 | $3.02 | $1003.20 | x |
| 1989-12-31 | $3.10 | $1003.20 | x |
| 1990-12-31 | $3.30 | $1003.20 | x |
| 1991-12-31 | $3.53 | $1003.20 | x |
| 1992-12-31 | $3.67 | $1003.20 | x |
| 1993-12-31 | $3.62 | $1003.20 | x |
| 1994-12-31 | $3.48 | $1003.20 | x |
| 1995-12-31 | $3.55 | $1003.20 | x |
| 1996-12-31 | $4.01 | $1003.20 | x |
| 1997-12-31 | $4.40 | $1003.20 | x |
| 1998-12-31 | $4.62 | $1003.20 | x |
| 1999-12-31 | $5.27 | $1003.20 | x |
| 2000-12-31 | $5.60 | $1003.20 | x |
| 2001-12-31 | $6.55 | $1003.20 | x |
| 2002-12-31 | $5.47 | $1003.20 | x |
| 2003-12-31 | $5.97 | $1003.20 | x |
| 2004-12-31 | $6.22 | $1003.20 | x |
| 2005-12-31 | $6.83 | $1003.20 | x |
| 2006-12-31 | $6.09 | $1003.20 | x |
| 2007-12-31 | $6.44 | $1003.20 | x |
| 2008-12-31 | $7.46 | $1003.20 | x |
| 2009-12-31 | $9.05 | $1003.20 | x |
| 2010-12-31 | $9.58 | $1003.20 | x |
| 2011-12-31 | $9.73 | $1003.20 | x |
| 2012-12-31 | $8.31 | $1003.20 | x |
| 2013-12-31 | $9.24 | $1003.20 | x |
| 2014-12-31 | $9.06 | $1003.20 | x |
| 2015-12-31 | $8.70 | $1003.20 | x |
| 2016-12-31 | $9.86 | $1003.20 | x |
| 2017-12-31 | $7.16 | $1003.20 | x |
| 2018-12-31 | $8.56 | $1003.20 | x |
| 2019-12-31 | $30.14 | $1003.20 | x |
| 2020-12-31 | $257.70 | $1003.20 | x |
| 2021-12-31 | $246.33 | $1003.20 | x |
| 2022-12-31 | $222.68 | $1003.20 | x |
| 2023-12-31 | $217.89 | $1003.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bristol-Myers Squibb Company PFD CONV 2 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 27.27%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.83%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 3.23x
- Recent ROE (27.27%) is below the historical average (27.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1987 | 22.46% | 14.13% | 1.01x | 1.58x | $592.50 Million |
| 1988 | 25.34% | 14.65% | 1.03x | 1.67x | $759.20 Million |
| 1989 | 14.69% | 8.13% | 1.08x | 1.67x | $238.60 Million |
| 1990 | 32.26% | 16.97% | 1.12x | 1.70x | $1.21 Billion |
| 1991 | 35.48% | 18.42% | 1.19x | 1.62x | $1.48 Billion |
| 1992 | 32.59% | 17.59% | 1.03x | 1.79x | $1.36 Billion |
| 1993 | 32.98% | 17.16% | 0.94x | 2.04x | $1.36 Billion |
| 1994 | 32.29% | 15.37% | 0.93x | 2.26x | $1.27 Billion |
| 1995 | 31.12% | 13.16% | 0.99x | 2.39x | $1.23 Billion |
| 1996 | 43.38% | 18.92% | 1.03x | 2.24x | $2.19 Billion |
| 1997 | 44.40% | 19.19% | 1.12x | 2.07x | $2.48 Billion |
| 1998 | 41.46% | 17.18% | 1.12x | 2.15x | $2.38 Billion |
| 1999 | 48.20% | 20.61% | 1.18x | 1.98x | $3.30 Billion |
| 2000 | 51.32% | 25.86% | 1.04x | 1.91x | $3.79 Billion |
| 2001 | 48.85% | 27.00% | 0.72x | 2.52x | $4.17 Billion |
| 2002 | 23.04% | 11.40% | 0.73x | 2.77x | $1.17 Billion |
| 2003 | 31.74% | 14.87% | 0.76x | 2.81x | $2.13 Billion |
| 2004 | 23.41% | 12.32% | 0.64x | 2.98x | $1.37 Billion |
| 2005 | 26.77% | 15.62% | 0.68x | 2.51x | $1.88 Billion |
| 2006 | 15.86% | 8.85% | 0.70x | 2.56x | $585.90 Million |
| 2007 | 20.50% | 11.19% | 0.74x | 2.48x | $1.11 Billion |
| 2008 | 42.86% | 25.47% | 0.70x | 2.41x | $4.02 Billion |
| 2009 | 71.49% | 56.42% | 0.61x | 2.09x | $9.13 Billion |
| 2010 | 19.74% | 15.92% | 0.63x | 1.98x | $1.53 Billion |
| 2011 | 23.25% | 17.46% | 0.64x | 2.07x | $2.11 Billion |
| 2012 | 14.39% | 11.12% | 0.49x | 2.64x | $597.70 Million |
| 2013 | 16.91% | 15.64% | 0.42x | 2.55x | $1.05 Billion |
| 2014 | 13.49% | 12.62% | 0.47x | 2.27x | $518.80 Million |
| 2015 | 11.38% | 9.81% | 0.52x | 2.23x | $197.40 Million |
| 2016 | 27.55% | 22.94% | 0.58x | 2.08x | $2.84 Billion |
| 2017 | 8.58% | 4.85% | 0.62x | 2.86x | $-167.10 Million |
| 2018 | 35.29% | 21.95% | 2.12x | 0.76x | $3.55 Billion |
| 2019 | 6.66% | 13.15% | 0.20x | 2.52x | $-1.72 Billion |
| 2020 | -23.78% | -21.16% | 0.36x | 3.13x | $-12.78 Billion |
| 2021 | 19.46% | 15.08% | 0.42x | 3.04x | $3.40 Billion |
| 2022 | 20.37% | 13.71% | 0.48x | 3.12x | $3.22 Billion |
| 2023 | 27.27% | 17.83% | 0.47x | 3.23x | $5.08 Billion |
Industry Comparison
This section compares Bristol-Myers Squibb Company PFD CONV 2's net assets metrics with peer companies in the Other industry.
Industry Context
- Industry: Other
- Average net assets among peers: $23,081,947,311
- Average return on equity (ROE) among peers: 33.09%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) | $17.20 Billion | 22.46% | 4.45x | $9.45 Million |
| Arçelik Anonim Sirketi (ACKAF) | $59.56 Billion | 12.87% | 3.33x | $19.95K |
| Argo Group US Inc. 6.5% SR NTS 42 (ARGD) | $1.23 Billion | -15.51% | 0.05x | $232.01K |
| American Crystal Sugar Company PFD REST NON DIV (ASCS) | $316.55 Million | 254.25% | 1.77x | $54.72 Million |
| Autobacs Seven Co. Ltd (ATBSF) | $127.35 Billion | 4.24% | 0.47x | $167.34K |
| Brookfield Asset Management Inc FR PRF PERPETUAL CAD 25 Ser 2 Cls A (BKFAF) | $11.77 Billion | 6.69% | 3.72x | $76.46K |
| BOL Bancshares Inc. PFD (BOLBP) | $11.94 Million | 0.62% | 6.68x | $0.91 |
| NYSE LISTED TEST STOCK FOR CTS AND CQS (CBO) | $3.36 Billion | 11.17% | 0.52x | $237.68K |
| Canadian Utilities Limited 2ND PFD SER Y (CNAUF) | $4.14 Billion | 10.45% | 1.28x | $142.90K |
| Central Parking Finance Trust PFD TR CV SECS (CRLKP) | $374.10 | 13.04% | 2.96x | $224.78K |